Compare BIO-TECHNE Corp (TECH) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Advanced Drainage Systems Inc — how do they compare? BIO-TECHNE Corp trades at $72.06 (market cap $11.24B), while Advanced Drainage Systems Inc trades at $143.52 (market cap $10.68B). The key difference: BIO-TECHNE Corp and Advanced Drainage Systems Inc are close in size by market cap, and Advanced Drainage Systems Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| TECH | WMS | |
|---|---|---|
Market Cap | $11.24B | $10.68B |
Sector | Health | Industrials |
52-Week High | $72.29 | $175.38 |
52-Week Low | $43.31 | $129.50 |
Enterprise Value | $11.32B | $12.29B |
Dividend Yield | 0.44% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.
The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
